StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.33−0.39 (-2.65%)

Close on Nov 18, 2026Market cap $779.08MP/E –Yield –

Beta Bionics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Beta Bionics's operating income for the twelve months ending Sep 30, 2026 was -$92.58M. For fiscal 2025 it was -$71.68M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$71.68M–
FY2024Dec 31, 2024-$45.25M–
FY2023Dec 31, 2023-$35.85M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$26.61M–
Q2 FY2026Jun 30, 2026-$25.58M–
Q1 FY2026Mar 31, 2026-$24.27M–
Q4 FY2025Dec 31, 2025-$16.12M–
Q3 FY2025Sep 30, 2025-$17.04M–
Q2 FY2025Jun 30, 2025-$19.87M–
Q1 FY2025Mar 31, 2025-$18.64M–
Q4 FY2024Dec 31, 2024-$13.04M–
Q3 FY2024Sep 30, 2024-$10.98M–
Q2 FY2024Jun 30, 2024-$11.78M–
Q1 FY2024Mar 31, 2024-$9.45M–

More Beta Bionics figures

See a number that looks wrong?